A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

Completed · Phase 1 · Has a placebo group

Conditions studied: Advanced Liver Fibrosis, Liver Cirrhosis

In brief

The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.

Key facts

Study ID

NCT05939947

Run by

Alentis Therapeutics AG

People needed

41

Starts

2023-04-01

Expected to finish

2024-10-30

Last updated by the study team

2024-12-03

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• American Research Corporation — San Antonio, Texas, United States
• APEX GmbH — Munich, Germany
• ARENSIA Exploratory Medicine S.R.L. — Bucharest, Romania
• ARENSIA Exploratory Medicine S.R.L. - Cluj-Napoca — Cluj-Napoca, Romania
• Summit Clinical Research — Bratislava, Slovakia
• Summit Clinical Research — Malacky, Slovakia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.